[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 23 2008

Oral Hypoglycemic Use and the SANDS Trial—Reply

JAMA. 2008;300(4):389-390. doi:10.1001/jama.300.4.389-b

In Reply: We agree with Dr Evans and colleagues that the uneven distribution of potential confounders is an important consideration in the interpretation of all trials. We have performed prespecified analyses exploring the potential role of glycemia or hypoglycemic drugs in our results. There were no significant differences between the aggressive and standard groups in the prevalence of metformin use (58% vs 53%, respectively; P = .29) and glitazone use (25% vs 24%, respectively; P = .65). The total percentages differ from Table 2 in the article because some patients were using both medications.

First Page Preview View Large
First page PDF preview
First page PDF preview
×